Phaseline

Targets › PRKAG2

PRKAG2 (5'-AMP-activated protein kinase subunit gamma-2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Cardiovascular; next expected readout May 2028.

AMP/ATP-binding subunit of AMP-activated protein kinase (AMPK), an energy sensor protein kinase that plays a key role in regulating cellular energy metabolism. In response to reduction of intracellular ATP levels, AMPK activates energy-producing pathways and inhibits energy-consuming processes: inhibits protein, carbohydrate and lipid biosynthesis, as well as cell growth and proliferation. (UniProt, Q9UGJ0)

Open in Phaseline: the race on PRKAG2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Atrium TherapeuticsATR 1072
siRNA targeting PRKAG2 to reduce gene expression
PRKAG2Phase 1Cardiac GlycogenosisMay 2028

Conditions

Cardiac Glycogenosis (1)

Modalities

small molecule (1)

Companies

Atrium Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.